A highly selective fluorescent probe for real-time imaging of bacterial NAT2 and high-throughput screening of natural inhibitors for tuberculosis therapy. (30th November 2018)

• Record Type: Journal Article
• Authors: Jin, Yinzhu; Tian, Zhenhao; Tian, Xiangge; Feng, Lei; Cui, Jingnan; Ma, Xiaochi
• Is Part Of: Materials chemistry frontiers. Volume 3:Number 1(2019)
• Page Start: 145
• Page End: 150
• Publication Date: 2018-11-30
• Subjects: Materials science -- Periodicals; Chemistry -- Periodicals; 540
• DOI: 10.1039/c8qm00514a
• Languages: English
• ISSNs: 2052-1529

Abstract

Abstract : Fluorescent probeARHB is developed for detecting in various bacteria the activity of N -acetyltransferase 2 (NAT2), a key enzyme in cell wall synthesis and widely considered to be a molecular target for anti-mycobacterial therapy. Abstract : N -Acetyltransferase 2 (NAT2) is a very important biologically functioning enzyme which plays a key role in the synthesis of cell walls in slowly growing mycobacteria. Thus, it has been widely considered to be a drug-target for anti-mycobacterial therapy. Herein, based on its catalytic characteristics, ARHB was developed for the real-time monitoring and assessment of the activity of NAT2 in different bacteria such as Mycobacterium, Staphylococcus aureus, Lactobacillus, and Pseudomonas aeruginosa . Moreover, using the highly sensitive probeARHB, a potent natural inhibitor (KSB-4 ) of NAT2 was found which could effectively inhibit Mycobacterium tuberculosis H37Ra for the first time. Furthermore, the bioactivity ofKSB-4 for treating tuberculosis was also evaluated in M. tuberculosis H37Ra, showing a minimum inhibitory concentration (MIC) of 25 μM. After treatment withKSB-4, M. tuberculosis H37Ra grew to be much shorter and its cell wall lysis was observed in scanning electron micrographs. All of the results fully demonstrated thatARHB could serve as a promising molecular tool for the rapid and real-time detection of NAT2 activity in a complex system, providing a novel high-throughput screening method for the discovery of new NAT2 inhibitors.